

Prof. Andrea Pfeifer - CEO of AC Immune – awarded Swiss Life Sciences/High-Tech Entrepreneur of the Year 2009

- Recognition of personal qualities and successful development of thriving biopharmaceutical company

Ecublens/Lausanne, Switzerland, October 24, 2009 – AC Immune SA, a leader in Alzheimer’s disease drug development, announced today that Ernst & Young awarded Prof. Andrea Pfeifer the Entrepreneur of the Year® 2009 Switzerland in the category Life Sciences/High-Tech. This intensive competition has been conducted annually in Switzerland since 1998 as part of Ernst & Young’s global program evaluating businessmen and women for their exceptional entrepreneurial achievements. The 2009 Swiss awards were given at a gala event held on the Novartis Campus in Basel.

Prof. Andrea Pfeifer, CEO of AC Immune, said: “It is a great honor for me personally and for all of the team at AC Immune to be chosen amongst our excellent peers in Switzerland. This award is a wonderful recognition of our achievements over the past six years to create a world-class biopharmaceutical company whose therapies promise so much hope to patients suffering from Alzheimer’s disease.”

“We have faced all sorts of risks in establishing AC Immune, but our courage and “passion to win” have enabled us to succeed. Switzerland has a century of tradition in leading the world in the Life Sciences/High-Tech sectors, and we must continue to support the spirit of our country’s entrepreneurs and ensure the successful flourishing of these new businesses in the coming decades. I would like to thank Ernst & Young for their commitment and engagement in this economically and socially important mission.”

Highlights of AC Immune’s achievements during the past year:

- Developed from a preclinical to a clinical company with three Alzheimer’s products in clinical trials in vaccines, antibodies and small molecules
- Validated Platform Technology specifically for central nervous system diseases and autoimmune diseases
- Successfully raised CHF 40 million in round C despite the difficult financial environment
- Established deal with Bayer Schering Pharma on brain imaging in clinical trial for Alzheimer’s patients
- Strengthened leadership team with Chief Financial Officer and Chief Medical Officer

About the Ernst & Young Entrepreneur of the Year 2009®

Ernst & Young is the only organization in the world to operate an international award scheme of this kind, based on standard criteria. Each year, 10,000 entrepreneurs in 50 different countries compete for the coveted title of Entrepreneur of the Year®. In Switzerland, 10 of the 48 entrepreneurial nominees made it through to the 2009 finals, satisfying the demanding criteria for the competition to find the Entrepreneur Of The Year®. The criteria look at the entrepreneur as an individual, the active role that he or she plays within the company, above-average growth, degree of innovation, international character and social commitment. The candidates are assessed by a qualified, independent jury. The selection process is complex: the members of the jury conduct intensive interviews with the finalists, visit the firms in person and inspect their annual financial statements.

About AC Immune SA

AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer's Disease drug development. AC Immune develops innovative therapeutics with "best in class" potential against Alzheimer's Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody for passive immunization is partnered with Genentech and entered Phase I in 2008. The company continues to develop in house the small molecule ACI-91 which entered Phase II in 2008 and the vaccine ACI-24 which commenced Phase I/IIa in 2009. These three clinical programs are focused on Alzheimer's disease, and are backed by a rich portfolio of preclinical compounds. The therapeutic molecules are also leveraged for Alzheimer's Disease diagnostic and other central nervous system and non-CNS diseases, such as Glaucoma. Since its foundation in 2003, AC Immune has raised CHF 64 million from private investors. The out-licensing agreement with Genentech was closed at the end of 2006 for a potential value of more than US\$ 300 million.

For further information, please contact:

Prof. Andrea Pfeifer
Chief Executive Officer
Phone: +41-21-693 91 21
E-mail: andrea.pfeifer@acimmune.com
www.acimmune.com

Eva Schier
Corporate Communications Manager
Phone: +41-21-693 91 34
E-mail: eva.schier@acimmune.com
www.acimmune.com